The company focuses on disease-specific 3D protein conformations, which exposes new binding sites (epitopes) not present on the same protein in healthy cells. This allows for highly selective drugs that avoid the toxicity common with targets defined by genetic sequence alone.

Traditional drug discovery separates finding a 'hit' from the long process of optimizing it into a drug candidate. DenovAI's 'one-shot' platform builds in advanced features from the start, collapsing a multi-year, disjointed process into a single, efficient design phase.

Contrary to the popular belief that antibody development is a bespoke craft, modern methods enable a reproducible, systematic engineering process. This allows for predictable creation of antibodies with specific properties, such as matching affinity for human and animal targets, a feat once considered a "flight of fancy."

Recludix succeeded in drugging SH2 domains, a target class abandoned in the 90s, by integrating five modern technologies. This platform includes proprietary DNA-encoded libraries, machine learning, a selectivity tool, novel crystallography methods, and a pro-drug approach to ensure cell permeability, demonstrating the complex approach needed for modern drug discovery breakthroughs.

Pharmaceutical companies like Pfizer have vast amounts of human genetic data (GWAS hits) linked to diseases but struggle to determine which are viable drug targets. Gordian's high-throughput in vivo screening directly tests the causal effects of hundreds of these targets, rapidly identifying the most promising candidates.

Inspired by the broad benefits of drugs like GLP-1s, Gordian is proactively creating "atlases" of target effects across multiple organs (heart, kidney, liver). This strategy positions them to discover the next class of drugs that treat multiple related conditions simultaneously, a key focus for their internal pipeline.

The company's R&D strategy pragmatically filters for targets that are not only highly validated and accessible with its current technology, but are also already on the radar of potential big pharma partners ("strategics"), indicating a clear market and potential exit path.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

The blockbuster drug bivalirudin was discovered as an unsanctioned "20% time" project at Biogen. This policy, allowing scientists to explore personal interests, demonstrates how institutionalizing freedom for undirected research can lead to major, company-defining breakthroughs that would otherwise be missed in a rigid R&D structure.